Low-grade astrocytomas and oligodendrogliomas

February 2013
National Guideline Clearinghouse;2013, p47
No abstract available.


Related Articles

  • Supratentorial Astrocytomas and Oligodendrogliomas Treated in the MRI Era. Sakata, Koh-ichi; Hareyama, Masato; Komae, Takashi; Shirato, Hiroki; Watanabe, Osamu; Watarai, Jiroh; Takai, Kenji; Yamada, Shogo; Tsuchida, Emiko; Sakai, Kunio // Japanese Journal of Clinical Oncology;Jun2001, Vol. 31 Issue 6, p240 

    Examines the treatment of supratentorial astrocytomas and oligodendrogliomas by magnetic resonance imaging. Policy for the treatment of patients with low-grade gliomas (LLG); Comparison between oligodendroglioma and astrocytoma; Sensitivity of LLG to chemotherapy.

  • Gene expression profiling and subgroup identification of oligodendrogliomas. Huang, Hervé; Okamoto, Yoshikazu; Yokoo, Hideaki; Heppner, Frank L.; Vital, Anne; Fevre-Montange, Michelle; Jouvet, Anne; Yonekawa, Yasuhiro; Lazaridis, Emmanuel N.; Kleihues, Paul; Ohgaki, Hiroko // Oncogene;8/5/2004, Vol. 23 Issue 35, p6012 

    The histological diagnosis of low-grade astrocytomas and oligodendrogliomas (WHO grade II) is often challenging, particularly in cases that show both astrocytic and oligodendroglial differentiation. We carried out gene expression profiling on 17 oligodendrogliomas (93% with LOH 1p and/or 19q)...

  • Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Watanabe, Takao; Nakamura, Mitsutoshi; Kros, Johan M.; Burkhard, Christoph; Yonekawa, Yasuhiro; Kleihues, Paul; Ohgaki, Hiroko // Acta Neuropathologica;Mar2002, Vol. 103 Issue 3, p267 

    Oligodendrogliomas typically show loss of heterozygosity (LOH) on chromosomes 1p and 19q, which correlates with their response to chemotherapy, whereas low-grade astrocytomas are characterized by frequent TP53 mutations and lack of sensitivity to alkylating therapeutic agents. Unequivocal...

  • Temozolomide in low-grade gliomas: living longer and better. Rees, Jeremy // Journal of Neurology, Neurosurgery & Psychiatry;Apr2015, Vol. 86 Issue 4, p359 

    In this article, the author talks about management of low-grade gliomas (LGGs) by using temozolomide in context with a study carried out by researcher J.A. Koekkoek and colleagues. Topics discussed include role of chemotherapy in managing LGGs, effect of oncological treatments on brain tumor...

  • A 31 -Year-Old Woman With a Transformed Low-grade Glioma. Warnke, Peter C. // JAMA: Journal of the American Medical Association;3/10/2010, Vol. 303 Issue 10, p967 

    The article offers clinical information on transformed low-grade glioma. It describes the clinical case of a 31-year-old health care professional who experienced tonic-clonic seizure and was found to have a primary brain tumor. The global epidemiology of low-grade gliomas in adults is explored,...

  • Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Okamoto, Yoshikazu; di Patre, Pier-Luigi; Burkhard, Christoph; Horstmann, Sonja; Jourde, Benjamin; Fahey, Michael; Schüler, Danielle; Probst-Hensch, Nicole M.; Yasargil, M. Gazi; Yonekawa, Yasuhiro; Lütolf, Urs M.; Kleihues, Paul; Ohgaki, Hiroko // Acta Neuropathologica;Jul2004, Vol. 108 Issue 1, p49 

    We carried out a population-based study on low-grade diffuse gliomas in the Canton of Zurich, Switzerland (population 1.16 million). From 1980 to 1994, 987 astrocytic and oligodendroglial tumors were diagnosed, of which 122 (12.4%) were low-grade (WHO grade II). The incidence rates adjusted to...

  • The role of surgery in the management of patients with diffuse low grade glioma. Aghi, Manish; Nahed, Brian; Sloan, Andrew; Ryken, Timothy; Kalkanis, Steven; Olson, Jeffrey // Journal of Neuro-Oncology;Dec2015, Vol. 125 Issue 3, p503 

    Question: Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? Target population: These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astrocytoma, or...

  • TP53 promoter methylation in human gliomas. Amatya, Vishwa Jeet; Naumann, Ulrike; Weller, Michael; Ohgaki, Hiroko // Acta Neuropathologica;Aug2005, Vol. 110 Issue 2, p178 

    Methylation of the promoter region of tumor suppressor genes may be associated with transcriptional silencing and tumor progression. The 5′ region of the TP53 gene does not contain a CpG island, but a basal promoter region of 85 bp is essential for its full promoter activity. In the...

  • Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. Michaud, Karine; de Tayrac, Marie; D’Astous, Myreille; Duval, Céline; Paquet, Claudie; Samassekou, Oumar; Gould, Peter Vincent; Saikali, Stéphan // PLoS ONE;12/28/2016, Vol. 11 Issue 12, p1 

    Objective: To study the feasibility and the diagnostic and prognostic interest of automated analysis of 1p, 19q, 9p and 10q status by FISH technique in oligodendroglial tumors. Methods: We analyzed a retrospective series of 33 consecutive gliomas with oligodendroglial histology (originally...

  • Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma. D'Urso, Pietro; D'Urso, Oscar; Storelli, Carlo; Catapano, Giuseppe; Gianfreda, Cosimo; Montinaro, Antonio; Muscella, Antonella; Marsigliante, Santo // Journal of Neuro-Oncology;Aug2011, Vol. 104 Issue 1, p113 

    Aberrant methylation of CpG islands in the promoter regions of tumour cells results in loss of gene function. In addition to genetic lesions, changes in the methylation profile of the promoters may be considered a factor for tumour-specific aberrant expression of the genes.We investigated the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics